Platelet compatibility of PLGA, chitosan and PLGA-chitosan nanoparticles

Nanomedicine

Volumn 4, Issue 7, 2009, Pages 735-746

  Li, Xue ^a   Radomski, Anna ^a   Corrigan, Owen I ^a   Tajber, Lidia ^a   Menezes, Fabio De Sousa ^a   Endter, Sibylle ^a   Medina, Carlos ^a   Radomski, Marek W ^a  

^a NONE

Author keywords

Biopolymers; Chitosan; GPIIb IIIa; Inhibition; Nanoparticles; P selectin; Platelet activation; Platelet aggregation; Poly(D,L lactide co glycolide)

Indexed keywords

BIOPOLYMER; CHITOSAN; FIBRINOGEN RECEPTOR; NANOPARTICLE; PADGEM PROTEIN; POLYGLACTIN; THROMBOCYTE RECEPTOR;

ARTICLE; BLOOD COMPATIBILITY; DEACETYLATION; DRUG DELIVERY SYSTEM; EMULSION; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; GELATION; HUMAN; IN VITRO STUDY; MOLECULAR WEIGHT; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

BLOOD PLATELETS; CHITOSAN; COLLAGEN; DRUG CARRIERS; FLOW CYTOMETRY; HUMANS; INTEGRIN BETA3; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NANOTECHNOLOGY; P-SELECTIN; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET-RICH PLASMA; POLYGLYCOLIC ACID; POLYMERS;

EID: 73549091667     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.65     Document Type: Article

References (36)

1. Koziara JM, Oh JJ, Akers WS, Ferraris SP, Mumper RJ: Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 22(11), 1821-1828 (2005).
2. Nemmar A, Hoet PH, Vanquickenborne B et al.: Passage of inhaled particles into the blood circulation in humans. Circulation 105(4), 411-414 (2002). • Describes how inhaled ultrafine carbon particles (<2.5 μm) pass into the systemic circulation and propose the link between air pollution and acute cardiovascular effects.
3. Nemmar A, Hoylaerts MF, Hoet PH, Nemery B: Possible mechanisms of the cardiovascular effects of inhaled particles: systemic translocation and prothrombotic effects. Toxicol. Lett. 149(1-3) 243-253 (2004). • Describes how inhaled ultrafine carbon particles (<2.5 μm) pass into the systemic circulation and propose the link between air pollution and acute cardiovascular effects.
4. Nemmar A, Hoylaerts MF, Hoet PH et al.: Ultrafine particles affect experimental thrombosis in an in vivo hamster model. Am. J. Respir. Crit. Care Med. 166(7), 998-1004 (2002). • Describes how inhaled ultrafine carbon particles (<2.5 μm) pass into the systemic circulation and propose the link between air pollution and acute cardiovascular effects.
5. Glynn MF, Movat HA, Murphy EA, Mustard JF: Study of platelet adhesiveness and aggregation with latex particles. J. Lab. Clin. Med. 65, 179-201 (1965).
6. Bloom G, Gustavson KH, Swensson A: On the reaction of the thrombocytes to submicroscopic particles in vitro. Acta Haematol. 13(1), 57-63 (1955).
7. 2 in the rat. Int. J. Hyg. Environ. Health 205(3), 239-244 (2002).
8. Duffin R, Tran CL, Clouter A et al.: The importance of surface area and specific reactivity in the acute pulmonary inflammatory response to particles. Ann. Occup. Hyg. 46(Suppl. 1), 242-245 (2002).
9. Pastorin G, Wu W, Wieckowski S et al.: Double functionalization of carbon nanotubes for multimodal drug delivery. Chem. Commun. 21(11), 1182-1184 (2006).
10. Yan A, Lau BW, Weissman BS et al.: Biocompatible, hydrophilic, supramolecular carbon nanoparticles for cell delivery. Adv. Mater. 18(18), 2373-2378 (2006).
11. Radomski A, Jurasz P, Alonso-Escolano D et al.: Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol. 146(6), 882-893 (2005). •• Pioneer contribution, describing how engineered and combustion-derived carbon nanoparticles cause human platelet aggregation in vitro and rat vascular thrombosis in vivo.
12. Miyamoto M, Sasakawa S, Ozawa T, Kawaguchi H, Ohtsuka Y: Platelet aggregation induced by latex particles. I. Effects of size, surface potential and hydrophobicity of particles. Biomaterials 10(4), 251-257 (1989). •• Comprehensive work on the different parameters of latex particles and their impact on platelet aggregation.
13. Miyamoto M, Sasakawa S, Ozawa T, Kawaguchi H, Ohtsuka Y: Mechanisms of blood coagulation induced by latex particles and the roles of blood cells. Biomaterials 11(6), 385-388 (1990).
14. Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ: Design of biodegradable particles for protein delivery. J. Control. Release 78(1-3), 15-24 (2002). • Design and characterization of some biodegradable nanoparticles as drug-delivery systems.
15. Nagamoto T, Hattori Y, Takayama K, Maitani Y: Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res. 21(4), 671-674 (2004).
16. Vila A, Sánchez A, Janes K et al.: Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57(1), 123-131 (2004).
17. Illum L: Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15(9), 1326-1331 (1998). •• Excellent review on the properties of chitosan and its uses in drug delivery systems.
18. Dornish M, Aarnold M, Skaugrud O: Alginate and chitosan: biodegradable biopolymers in drug delivery systems. Eur. J. Pharm. Sci. 4(Suppl. 1) S153 (1996).
19. Corrigan OI, Li X: Quantifying drug release from PLGA nanoparticulates. Eur. J. Pharm. Sci. 37(3-4), 477-485 (2009).
20. Leane MM, Nankervis R, Smith A, Illum L: Use of the ninhydrin assay to measure the release of chitosan from oral solid dosage forms. Int. J. Pharm. 271(1-2), 241-249 (2004).
21. Corrigan DO, Healy AM, Corrigan OI: Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur. J. Pharm. Biopharm. 62(3), 295-305 (2005).
22. Hirai A, Odani H, Nakajima A: Determination of degree of deacetylation of chitosan by 1H NMR spectroscopy. Polym. Bull. 26(1), 87-94 (1991).
23. Liao CM, Chiang YH, Chio CP: Model-based assessment for human inhalation exposure risk to airborne nano/fine titanium dioxide particles. Sci. Total Environ. 407(1), 165-177 (2008).
24. Bozkir A, Saka OM: Chitosan nanoparticles for plasmid DNA delivery: effect of chitosan molecular structure on formulation and release characteristics. Drug Deliv. 11(2), 107-112 (2004).
25. Cho M, Sah H: Formulation and process parameters affecting protein encapsulation into PLGA microspheres during ethyl acetate-based microencapsulation process. J. Microencapsul. 22(1) 1-12 (2005).
26. Berthold A, Cremer K, Kreuter J: Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs. J. Control. Release 39(1), 17-25 (1996).
27. Mao HQ, Roy K, Troung-Le VL et al.: Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release 70, 399-421 (2001).
28. Chung AWY, Jurasz P, Hollenberg MD, Radomski MW: Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br. J. Pharmacol. 135(5), 1123-1132 (2002).
29. Kneuer C, Ehrhardt C, Radomski MW, Bakowsky U: Selectins - potential pharmacological targets? Drug Discov. Today 11(21-22), 1034-1040 (2006).
30. Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW: Metalloproteinases in platelet function. Thromb. Res. 121(4), 535-542 (2008).
31. Sagnella S, Mai-Ngam K: Chitosan based surfactant polymers designed to improve blood compatibility on biomaterials. Colloids Surf. B Biointerfaces 42(2), 147-155 (2005). • Describes the strategies employed to modify the surface of biomaterials in order to improve their blood compatibility.
32. Groth T, Klosz K, Campbell EJ, New RR, Hall B, Goering H: Protein adsorption, lymphocyte adhesion and platelet adhesion/ activation on polyurethane ureas is related to hard segment content and composition. J. Biomater. Sci. Polym. Ed. 6(6), 497-510 (1994).
33. Lee JH, Ju YM, Lee WK, Park KD, Kim YH: Platelet adhesion onto segmented polyurethane surfaces modified by PEO- and sulfonated PEO-containing block copolymer additives. J. Biomed. Mater. Res. 40(2), 314-323 (1998).
34. +/H+ exchanger. J. Biomed. Sci. 11(1), 19-26 (2003).
35. Cenni E, Granchi D, Avnet S, Fotia C, Salerno M: Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 29(10), 1400-1411 (2008).
36. Kainthan RK, Gnanamani M, Ganguli M, Ghosh T, Brooks DE: Blood compatibility of novel water soluble hyperbranched polyglycerol-based multivalent cationic polymers and their interaction with DNA. Biomaterials 27(31), 5377-5390 (2006).